Comment on: Long-acting glycopeptides: what are the barriers to access in patients who need them most, and how can they be overcome?
Journal of Antimicrobial Chemotherapy · 04.03.2026 · 81 (4)
DOI: 10.1093/jac/dkag102 ↗Kurz gefasst
Editorial in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 18.03.2026. Verfasst von Marco Bongiovanni. Beteiligte Einrichtung: Division of Infectious Diseases, Ente Ospedaliero Cantonale, Lugano, Switzerland. Die Arbeit nennt 6 Literaturangaben.
Abstract (Originalsprache)
Dear Editor, The recent paper by MacPhail et al.1 published in the Journal of Antimicrobial Chemotherapy, addresses an important topic as clinicians increasingly seek antimicrobial strategies that are effective, feasible and aligned with antimicrobial stewardship principles. Long-acting glycopeptides (LGPs), particularly dalbavancin and oritavancin, may represent a meaningful advance for selected invasive Gram-positive infections, especially in patients for whom conventional inpatient therapy or outpatient parenteral antimicrobial therapy (OPAT) is difficult. Two practical aspects warrant emphasis—antimicrobial stewardship and reduced hospitalization—while acknowledging the main barrier to broader implementation: the lack of standardized, evidence-based dosing schedules for off-label, prolonged or multi-dose regimens. The prolonged half-life of LGPs allows infrequent administration, reducing reliance on daily intravenous therapy. In routine practice, prolonged hospitalization is often dictated by the logistics of antibiotic delivery rather than ongoing clinical instability. LGPs may therefore shorten avoidable inpatient stays while maintaining intended parenteral exposure. This can reduce catheter-related complications, lower the risk of nosocomial infections and improve patient quality of life. At a system level, earlier discharge improves bed availability and hospital flow—outcomes often underestimated in analyses focused primarily on acquisition costs.
Autor:innen und Institutionen
- Division of Infectious Diseases, Ente Ospedaliero Cantonale, Lugano, Switzerland.
- Department of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland.
ORCID-Profile: Marco Bongiovanni
Zitieren
APA
Bongiovanni, M. (2026). Comment on: Long-acting glycopeptides: what are the barriers to access in patients who need them most, and how can they be overcome?. Journal of Antimicrobial Chemotherapy, 81(4). https://doi.org/10.1093/jac/dkag102
Vancouver
Bongiovanni M. Comment on: Long-acting glycopeptides: what are the barriers to access in patients who need them most, and how can they be overcome?. Journal of Antimicrobial Chemotherapy. 2026;81(4). doi:10.1093/jac/dkag102
BibTeX
@article{Bongiovanni2026,
author = {Bongiovanni, Marco},
title = {Comment on: Long-acting glycopeptides: what are the barriers to access in patients who need them most, and how can they be overcome?},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
volume = {81},
number = {4},
doi = {10.1093/jac/dkag102}
}
EUVIMED